Radnostix Finalizes Landmark Agreement to Sell Key Nuclear Assets to NANO Nuclear

Radnostix, Inc. (previously known as International Isotopes Inc.) is making headlines with a transformative agreement that could realign its business focus and strengthen its financial standing. On October 1, 2026, the company announced a definitive agreement regarding the divestiture of its depleted uranium hexafluoride (DUF6) and fluorine-related assets to NANO Nuclear Energy Inc. This significant move also includes its wholly-owned subsidiary, International Isotopes Fluorine Products, Inc.

The deal, valued at approximately $13.5 million, comprises $9.5 million in cash and $4 million in NANO common stock. This financial structure conveys Radnostix's confidence in NANO’s capability to successfully develop these assets, thus playing an essential role in the U.S. Nuclear Fuel Cycle industry. Shahe Bagerdjian, CEO of Radnostix, expressed strong faith in NANO, applauding their strategic direction toward becoming a vertically integrated nuclear energy company.

Understanding the Assets Up for Sale

The transaction pertains to the acquisition of critical nuclear fuel processing assets, including an invaluable U.S. Nuclear Regulatory Commission (NRC) license along with intellectual property and technical documentation associated with DUF6 deconversion and fluorine extraction processes. This facility was intended to be set up in Lea County, New Mexico, though it had not yet been constructed when the agreement was reached.

With this transfer, NANO Nuclear will gain access to licensed fuel cycle assets and an extensive collection of regulatory and technical work accomplished thus far. Bagerdjian emphasized that this move would enable Radnostix to focus on its core competencies in radioisotope technologies while reaping the benefits of its new stake in NANO. This is not merely a divestiture but a strategic pivot aimed at enhancing Radnostix's growth in other critical areas of its business.

The Bigger Picture: Radnostix's Core Focus

The proceeds from this deal will allow Radnostix to expedite its growth initiatives across its four diverse radioisotope technology segments. This includes a variety of products used in medical applications, such as radionuclide therapies where Radnostix already has a formidable presence.

In recent years, Radnostix has been diligently working on developing a mixed portfolio that includes generic sodium iodide I-131 for hyperthyroidism and thyroid cancer treatments. The company also engages in contract manufacturing of drug products and supplies radioisotope APIs to third-party clients in the theranostics sector.

Bagerdjian anticipates that the funds from this transaction will fuel further research and development efforts, leading to organic growth while also enabling possible future acquisitions. He proudly stated that the deal allows the company to maintain upside potential via NANO stock while fully concentrating on its advancements in medical and industrial radioisotope applications.

Anticipated Timeline and Future Developments

The completion of the asset purchase transaction remains pending regulatory approvals and site arrangements, particularly from the NRC and New Mexico officials. Closing is expected to occur within 90 to 120 days if everything goes as planned, setting the stage for Radnostix to enhance its product offerings and market capabilities in the radioisotope sector.

As the nuclear energy landscape continues to evolve, companies like Radnostix must remain agile and strategic in their operations. This recent move not only signifies a major transition for Radnostix but also reinforces its commitment to playing a crucial role in advancing nuclear technologies that are essential for both medical and industrial applications. Given the growing global emphasis on clean and efficient energy, this strategic maneuver positions Radnostix for exciting growth opportunities ahead.